{"id":"NCT01584843","sponsor":"GlaxoSmithKline","briefTitle":"Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus","officialTitle":"A Multicenter, Randomized, Evaluator-masked, Parallel-group, Non-treatment-controlled Study Followed by an Open-label Study to Evaluate Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2013-07","completion":"2014-06","firstPosted":"2012-04-25","resultsPosted":"2014-08-01","lastUpdate":"2015-07-24"},"enrollment":41,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Strabismus"],"interventions":[{"type":"DRUG","name":"GSK1358820","otherNames":["Botulinum Toxin Type A"]}],"arms":[{"label":"Non-treatment (10-20 PD)","type":"NO_INTERVENTION"},{"label":"GSK1358820 1.25 U (10-20 PD)","type":"ACTIVE_COMPARATOR"},{"label":"GSK1358820 2.5 U (10-20 PD)","type":"ACTIVE_COMPARATOR"},{"label":"Non-treatment (20-50 PD)","type":"NO_INTERVENTION"},{"label":"GSK1358820 2.5 U (20-50 PD)","type":"ACTIVE_COMPARATOR"},{"label":"GSK1358820 5.0 U (20-50 PD)","type":"ACTIVE_COMPARATOR"}],"summary":"Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820 compared with non-treatment in patients with strabismus based on angles of strabismus in the primary position.","primaryOutcome":{"measure":"Change From Baseline in Strabismus Angle Prism Dioptre (PD) in the Primary Position at Week 4 of the FTP in Observed Cases (OC)","timeFrame":"Baseline and Week 4 of the FTP","effectByArm":[{"arm":"BSA >=10 PD and <20 PD: Non-treatment, Then GSK1358820","deltaMin":2.33,"sd":6.602},{"arm":"BSA >=10 PD and <20 PD: GSK1358820 1.25 U","deltaMin":-7.5,"sd":7.141},{"arm":"BSA >=10 PD and <20 PD: GSK1358820 2.5 U","deltaMin":-3.75,"sd":2.475},{"arm":"SA >=20 PD and <50 PD: Non-treatment, Then GSK1358820","deltaMin":-0.55,"sd":2.291},{"arm":"BSA >=20 PD and <50 PD: GSK1358820 2.5 U","deltaMin":-13.4,"sd":15.105},{"arm":"BSA >=20 PD and <50 PD: GSK1358820 5.0 U","deltaMin":-17.27,"sd":15.476}],"pValues":[{"comp":"OG000 vs OG001","p":"0.091"},{"comp":"OG000 vs OG002","p":"0.338"},{"comp":"OG001 vs OG002","p":"0.524"},{"comp":"OG003 vs OG004","p":"0.031"},{"comp":"OG003 vs OG005","p":"0.005"},{"comp":"OG004 vs OG005","p":"0.490"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":24},"locations":{"siteCount":13,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Eyelid ptosis","Nasopharyngitis","Conjunctival haemorrhage","Conjunctival hyperaemia","Diplopia"]}}